G
Glenn S. Van Aller
Researcher at GlaxoSmithKline
Publications - 27
Citations - 4725
Glenn S. Van Aller is an academic researcher from GlaxoSmithKline. The author has contributed to research in topics: Histone methyltransferase & EZH2. The author has an hindex of 18, co-authored 27 publications receiving 4182 citations.
Papers
More filters
Journal ArticleDOI
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations.
Michael T. McCabe,Heidi M. Ott,Gopinath Ganji,Susan Korenchuk,Christine Thompson,Glenn S. Van Aller,Yan Liu,Alan P. Graves,Anthony Della Pietra,Elsie Diaz,Louis V. LaFrance,Mellinger Mark,Celine Duquenne,Xinrong Tian,Ryan G. Kruger,Charles F. McHugh,Martin Brandt,William H. Miller,Dashyant Dhanak,Sharad K. Verma,Peter J. Tummino,Caretha L. Creasy +21 more
TL;DR: GSK126, a potent, highly selective, S-adenosyl-methionine-competitive, small-molecule inhibitor of EZH2 methyltransferase activity, decreases global H3K27me3 levels and reactivates silenced PRC2 target genes and markedly inhibits the growth of EzH2 mutant DLBCL xenografts in mice are demonstrated.
Journal ArticleDOI
EZH2 Is Required for Germinal Center Formation and Somatic EZH2 Mutations Promote Lymphoid Transformation
Wendy Béguelin,Relja Popovic,Matt Teater,Yanwen Jiang,Karen L. Bunting,Monica Rosen,Hao Shen,Shao Ning Yang,Ling Wang,Teresa Ezponda,Eva Martinez-Garcia,Haikuo Zhang,Yupeng Zheng,Sharad K. Verma,Michael T. McCabe,Heidi M. Ott,Glenn S. Van Aller,Ryan G. Kruger,Yan Liu,Charles F. McHugh,David Scott,Young Rock Chung,Neil L. Kelleher,Rita Shaknovich,Caretha L. Creasy,Randy D. Gascoyne,Kwok-Kin Wong,Leandro Cerchietti,Ross L. Levine,Omar Abdel-Wahab,Jonathan D. Licht,Olivier Elemento,Ari Melnick +32 more
TL;DR: GC B cell (GCB)-type diffuse large B cell lymphomas (DLBCLs) are mostly addicted to EZH2 but not the more differentiated activated B cell(ABC)-type DLBCLS, thus clarifying the therapeutic scope of EZh2 targeting.
Journal ArticleDOI
A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC.
Helai P. Mohammad,Kimberly N. Smitheman,Chandrashekhar D. Kamat,David Soong,Kelly Federowicz,Glenn S. Van Aller,Jessica L. Schneck,Jeffrey D. Carson,Yan Liu,Michael Butticello,William G. Bonnette,Shelby A. Gorman,Yan Degenhardt,Yuchen Bai,Michael T. McCabe,Melissa B. Pappalardi,Kasparec Jiri,Xinrong Tian,Mcnulty Kenneth C,Rouse Meagan B,Patrick McDevitt,Thau F. Ho,Michelle Crouthamel,Timothy K. Hart,Nestor O. Concha,Charles F. McHugh,William H. Miller,Dashyant Dhanak,Peter J. Tummino,Christopher L. Carpenter,Johnson Neil W,Christine L. Hann,Ryan G. Kruger +32 more
TL;DR: A proliferation screen of cell lines representing a number of tumor types indicated that small cell lung carcinoma (SCLC) is sensitive to LSD1 inhibition, and a subset of SCLC lines and primary samples that undergo growth inhibition in response to GSK2879552 exhibit DNA hypomethylation of a signature set of probes, suggesting this may be used as a predictive biomarker of activity.
Journal ArticleDOI
Identification of Potent, Selective, Cell-Active Inhibitors of the Histone Lysine Methyltransferase EZH2.
Sharad K. Verma,Xinrong Tian,Louis V. LaFrance,Celine Duquenne,Dominic Suarez,Kenneth A. Newlander,Stuart Paul Romeril,Joelle Lorraine Burgess,Seth W. Grant,Brackley James,Alan P. Graves,Daryl A. Scherzer,Art Shu,Christine Thompson,Heidi M. Ott,Glenn S. Van Aller,Carl A. Machutta,Elsie Diaz,Yong Jiang,Johnson Neil W,Steven D. Knight,Ryan G. Kruger,Michael T. McCabe,Dashyant Dhanak,Peter J. Tummino,Caretha L. Creasy,William H. Miller +26 more
TL;DR: This work has identified highly potent, selective, SAM-competitive, and cell-active EZH2 inhibitors, including GSK926 and GSK343, which are small molecule chemical tools that would be useful to further explore the biology of EZh2.
Journal ArticleDOI
Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin
Steven D. Knight,Nicholas D. Adams,Joelle Lorraine Burgess,Amita M. Chaudhari,Michael G. Darcy,Carla A. Donatelli,Juan I. Luengo,Ken A. Newlander,Cynthia A. Parrish,Lance Ridgers,Martha A. Sarpong,Schmidt Stanley J,Glenn S. Van Aller,Jeffrey D. Carson,Melody Diamond,Patricia A. Elkins,Christine M. Gardiner,Eric Garver,Seth A. Gilbert,Richard R. Gontarek,Jeffrey R. Jackson,Kevin L. Kershner,Lusong Luo,Kaushik Raha,Christian S. Sherk,Chiu-Mei Sung,David Sutton,Peter J. Tummino,Ronald Wegrzyn,Kurt R. Auger,Dashyant Dhanak +30 more
TL;DR: 2,4-Difluoro-N-{2-(methyloxy)-5-[4-(4-pyridazinyl)-6-quinolinyl]-3- pyridinyl}benzenesulfonamide (GSK2126458, 1) has been identified as a highly potent, orally bioavailable inhibitor of PI3Kα and mTOR with in vivo activity in both pharmacodynamic and tumor growth efficacy models.